pimecrolimus and clobetasol + clobetasol 0.05% cream
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lichen Sclerosus
Conditions
Lichen Sclerosus
Trial Timeline
Oct 1, 2006 → Oct 1, 2009
NCT ID
NCT00393263About pimecrolimus and clobetasol + clobetasol 0.05% cream
pimecrolimus and clobetasol + clobetasol 0.05% cream is a phase 2 stage product being developed by Novartis for Lichen Sclerosus. The current trial status is completed. This product is registered under clinical trial identifier NCT00393263. Target conditions include Lichen Sclerosus.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00393263 | Phase 2 | Completed |
Competing Products
12 competing products in Lichen Sclerosus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LP-10 (Liposomal Tacrolimus) | Lipella Pharmaceuticals | Phase 2 | 44 |
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 52 |
| Baricitinib 4 milligram Oral Tablet | Eli Lilly | Phase 2 | 52 |
| Pimecrolimus 1% cream | Novartis | Phase 2 | 52 |
| secukinumab 300 mg Q4W + secukinumab 300 mg Q2W | Novartis | Phase 2 | 52 |
| Apremilast + Placebo | Amgen | Phase 2 | 51 |
| Deucravacitinib | Bristol Myers Squibb | Phase 2 | 51 |
| Dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| Dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| Amevive (Alefacept) + Placebo | Biogen | Phase 2 | 49 |
| Ruxolitinib cream + Vehicle cream | Incyte | Phase 2 | 49 |
| Ruxolitinib cream + Vehicle cream | Incyte | Phase 2 | 49 |